In this study, 249 mice who were identified with SCC tumours received treatment with a range of drug regimens. Over the course of 45 days, tumour development was observed and measured. The purpose of this study was to compare the performance of Pymaceuticalsâ€™ drug of interest, Capomulin, against the other treatment regimens.
